Peer Review History
| Original SubmissionJune 11, 2024 |
|---|
|
Dear Dr. Safren, The study is relevant and timely. The findings have potential to inform the literature in this area. However, there are concerns about the intersectionality framework used in this study. Specifically, some of the arguments made in support of this framework appear to be in conflict with intersectionality. This may potentially skew the methods and findings. Please address these and other concerns raised by Reviewer 2 in both your Response to Reviewers and manuscript revisions. Please submit your revised manuscript by Oct 11 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Magdalena Szaflarski, PhD Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following financial disclosure: [Data collection for this study was supported by the National Institute of Allergy and Infectious Disease (NIAID) (URL: https://www.niaid.nih.gov/) (P30AI073961 – PI Pawha) and the National Institute of Mental Health (NIMH) (URL: https://www.nimh.nih.gov/) (1P30MH133399 – PI Safren). Some author time was supported by the National Institute on Drug Abuse (NIDA) (URL: https://nida.nih.gov/) (R36DA058563-01A – PI Weinstein). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.]. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. In the online submission form, you indicated that [Data cannot be shared publicly due to concerns regarding confidentiality. Researchers can contact the senior author to request access to the data. All requests will go through the University of Miami IRB via proposed amendments, and researchers who meet the criteria for access to the confidential data will receive access via a secure, password- protected link to a University of Miami Box folder.]. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Very relevant research question with results and conclusions which will add significantly to current gaps in literature in HIV prevention. Especially excited to see the addition of age over 50 as SDOH as the epidemic continues to grow older. Excellent job. Just a few typos- ie pg 6 line 5 replace tan with than. Reviewer #2: I would like to thank the authors and editor for the opportunity to review this interesting manuscript that explores some very important intersectional ideas. I have several concerns about the framing and methods that are outlined below. I hope that these will be taken as helpful and constructive as they are intended. Introduction: 1. At the end of the second paragraph, the authors discuss misleading narratives about HIV and include, “(e.g., 4 H’s, GRID Disease).” Given the amount of time that has passed since these terms were used, and the standard practice of spelling out acronyms the first time they are used, these need to be spelled out. Further, simply spelling them out with no explanation may not convey what the authors are trying to say. Some may not have the historical knowledge to make sense of them. Lastly, the ‘D’ in GRID is disease so no need to say “Disease” after it. 2. While I applaud the use of intersectionality in this work, there are some ways in which the authors frame their arguments that are in conflict with the very tenets of intersectionality. For example, at the bottom of page 4, the authors state that PLWH experience “additional forms of stigma, unrelated to their HIV status,” and in the first sentence of the first full paragraph on page 5 that “minorities are subject to compounded experiences of stigma.” In an intersectional framing, those “additional forms of stigma” are not “unrelated to their HIV status.” One’s experience of racism or sexism is, in part, shaped by their HIV status and vice versa. For example, HIV stigma may take the shape of shaming a woman for being a bad mother because of her HIV status, or sexist framings of risk could blame her for being irresponsible as though her male partner had no role to play in her HIV acquisition. Second, the terms ‘compounded’ or ‘layered’ are also not consistent with intersectionality, as they imply that these experiences of stigma and oppression can be added up vs seeing them as co-constitutive and multiplicative. 3. At the bottom of page 5, the authors describe that “race, ethnicity, age, gender, and sexual orientation are traditional social determinants of health. It is essential that this be reframed. Race, itself, is not a SDOH; Racism is the SDOH. There is nothing inherent in one’s racial, ethnic, or sexual identity that determines health outcomes. It is the oppressions they are subjected to. This is also in conflict with intersectionality as intersectionality goes beyond identities and points to structure. This sentence goes on to state that “certain combinations of intersecting identities may foster resilience.” This, once again, centers identities, and I am not sure what this statement means. a.This same reframing is needed in the third to last line on page 6 where the authors state that “outcomes, such as stigma, occur because of the interactions between identities b.That identities are SDOH is restated in the first sentence under ‘Marginalized-group identity variables’ on page 8. 4. The very next sentence at the bottom of page 5 states that “greater racial diversity is associated with reduced internalized stigma,” but what does “greater racial diversity” mean? The magnitude of diversity is not an individual measure. Methods 1. For the race category, I am confused as to why the authors decided to split the group into white and non-white when 95% of this sample is either Black or white. The “non-white” findings are likely reflecting the experiences of Black participants. If so, then this analysis and the findings need to be discussed specifically in that context. The authors have combined 862 Black participants with 63 participants that are divided into 5 other racial categories. It is unlikely that these data support making claims about all non-white people in this sample. 2. Similarly, nearly all of your participants were cis men/cis women. So, make your analysis about that. You don’t have enough Trans folks to make statements about them so you shouldn’t. 3. When it comes to Hispanic ethnicity, were there differences for Black H/NH vs White H/NH? 4. It is unclear why the authors chose to only include two-way interactions in the models. Given the use of intersectionality, it would be important to explore stigma among Black gay men, White heterosexual men, Black Hispanic lesbian women, etc. By treating these two-way interactions as discrete, as though they function independently of the other axes of identity that you have in your data undermines the intersectional analysis and weakens contribution of this framework. Results My only comment on the results is that they reflect the choices made on the methods as I describe above. I think they could be much stronger with a more robust intersectional analysis. Discussion 1. The first sentence, once again, says that this study examined “intersecting social determinants of health.” But the authors measured identities not social determinants. This is repeated again in the third sentence. 2. In the third paragraph (page 17), the authors state, “findings in this study suggest that older adults’ experiences of internalized HIV stigma vary depending on a variety of cultural values, syndemic factors, and experiences with other types of structural stigma.” However, nothing in these findings support such a statement. There is no exploration of cultural values, syndemic factors, experiences with structural stigma in this study. In the very next sentence, the authors state again that stigma results “from intersecting identities.” (See comment#3 on the introduction.) ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Pamela Payne Foster Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Dear Dr. Safren, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== While the authors have made commendable efforts in addressing the reviewers’ comments, a few minor issues remain, please address the following points:
Could you please carefully revise the manuscript to address all comments raised? ============================== Please submit your revised manuscript by Jul 14 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Zahra Al-Khateeb, Ph.D Staff Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Reviewer #1: This is a revision review. The authors provided adequate revisions or through explanations to support their perspectives. These revisions meet the criteria for publication. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Pamela H Foster ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org |
| Revision 2 |
|
Multiple-marginalized identities and internalized HIV stigma among people living with HIV in South Florida: an intersectional approach PONE-D-24-23097R2 Dear Dr. Safren, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Laura Kelly, PhD Division Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .